Interestingly, the studies of Shamsi et al. [57] demonstrated the moderate micromolar MARK4 inhibiting action for known AD drugs acting as AChE inhibitors, i.e., donepezil and rivastigmine; slightly more potent in the case of donepezil (Figure 6c). This evidence concerns the gene MARK4 and Alzheimer disease.